Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Genfit S.A. (GNFT)

3.55   -0.04 (-1.11%) 12-07 15:59
Open: 3.53 Pre. Close: 3.59
High: 3.65 Low: 3.515
Volume: 12,797 Market Cap: 177(M)

Technical analysis

as of: 2022-12-07 4:22:39 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.67     One year: 5.02
Support: Support1: 3.51    Support2: 2.92
Resistance: Resistance1: 4    Resistance2: 4.3
Pivot: 3.77
Moving Average: MA(5): 3.66     MA(20): 3.82
MA(100): 4.09     MA(250): 3.98
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 12.5     %D(3): 16.4
RSI: RSI(14): 42
52-week: High: 6.38  Low: 3.01
Average Vol(K): 3-Month: 22 (K)  10-Days: 9 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNFT ] has closed above bottom band by 20.6%. Bollinger Bands are 21.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.65 - 3.67 3.67 - 3.69
Low: 3.47 - 3.49 3.49 - 3.51
Close: 3.6 - 3.63 3.63 - 3.66

Company Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Headline News

Tue, 29 Nov 2022
Inflation Decline in Germany, Spain Helps Boost European Equities - InvestorsObserver

Wed, 23 Nov 2022
A Long Wait For Genfit May Be Worth It (NASDAQ:GNFT) - Seeking Alpha

Thu, 17 Nov 2022
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases - Yahoo Finance

Thu, 10 Nov 2022
GENFIT Reports Third Quarter 2022 Financial Information -

Thu, 10 Nov 2022
Genfit reports Q3 results (NASDAQ:GNFT) - Seeking Alpha

Thu, 29 Sep 2022
GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 50 (M)
Shares Float 44 (M)
% Held by Insiders 0 (%)
% Held by Institutions 4.5 (%)
Shares Short 131 (K)
Shares Short P.Month 176 (K)

Stock Financials

EPS 0.85
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.2
Profit Margin (%) 50.7
Operating Margin (%) 48.2
Return on Assets (ttm) 15.3
Return on Equity (ttm) 67.4
Qtrly Rev. Growth 273.1
Gross Profit (p.s.) 1.71
Sales Per Share 1.89
EBITDA (p.s.) 0.95
Qtrly Earnings Growth 0
Operating Cash Flow 80 (M)
Levered Free Cash Flow 35 (M)

Stock Valuations

PE Ratio 4.27
PEG Ratio 0
Price to Book value 1.64
Price to Sales 1.91
Price to Cash Flow 2.25

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.